文献速递流行病学与生物统计临床试验与 GCP

进展性疾病纵向试验的时间尺度目标参数与两步估计

Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases.
PubMed 文献 · Stat Med · 2026-01-01

针对阿尔茨海默病等进展性疾病,固定时点的均值差可能低估早期治疗对延缓进展的意义。作者提出时间尺度目标参数(如节省时间或进展减缓百分比)及两步估计法,在随机试验中识别,并用模拟研究和一项阿尔茨海默病2/3期试验评估。

要点

  • 时间尺度参数可量化治疗延缓进展的时间获益,补充固定时点均值差。
  • 两步估计第一步用标准纵向方法,第二步基于汇总统计量推断目标参数。
  • 方法在阿尔茨海默病2/3期试验中提供治疗效应的重要额外洞察。

核心结论

  • 时间尺度目标参数能更直观地表达进展性疾病治疗对延缓进程的效应。
  • 所提出的两步估计法具有可研究的渐近性质和效率,并已实现于TCT R包。

研究设计与样本

  • 方法学研究,提出时间尺度目标参数类并在随机试验正则假设下识别。
  • 提出两步估计法,通过广泛模拟研究评估其渐近性质和效率。
  • 应用于一项阿尔茨海默病2/3期临床试验的数据分析。

主要发现

  • 固定时点均值差在疾病早期可能较小,但可对应重要的进展减缓。
  • 两步估计法第一步可用标准纵向数据方法和软件分析。
  • 第二步利用第一步的汇总统计量推断目标参数,已在TCT R包实现。
  • 在阿尔茨海默病2/3期试验中获得对治疗效应的重要额外洞察。

临床怎么用

  • 在进展性疾病纵向随机试验中,可补充报告时间节省或进展减缓百分比等时间尺度参数。
  • 使用两步估计时,第一步采用标准纵向分析方法,第二步基于汇总统计量推断。
  • 可借助TCT R包实现第二步估计。

局限性

  • 若治疗非随机化,目标参数虽仍定义明确,但识别需要额外不可检验假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In progressive diseases such as Alzheimer's, treatments that slow progression should start early to preserve higher levels of functioning for a longer period. In corresponding clinical trials, treatment effects are usually expressed as mean differences on a clinical scale at fixed time points. Early in the disease course, however, these mean differences may appear small but may nonetheless correspond to an important slowing of disease progression. This complicates the appreciation of the relevance of observed treatment effects. We introduce a class of target parameters that quantify treatment effects on the time scale in longitudinal studies; for instance, in terms of time saved or percentage slowing of progression. We focus on data from randomized trials where the target parameters are identified under regularity assumptions. These target parameters remain well defined if treatment was not randomized, but additional untestable assumptions are required for identification. We propose general two-step estimators. In the first step, the data can be analyzed with standard methods for longitudinal data and standard software can thus be used. In the second step, summary statistics from the first step are used for inferences about the target parameters. The second step has been implemented in the TCT R package. We study the asymptotic properties and efficiency of these two-step estimators, and evaluate them in an extensive simulation study. These estimators are used in a phase 2/3 clinical trial for Alzheimer's disease, leading to important additional insights into the treatment effect.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Stijven F, Mallinckrodt C, Molenberghs G, et al. Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases. Stat Med. 2026. PMID: 42151713. doi:10.1002/sim.70591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。